Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Weekly Carfilzomib + Dexamethasone in Relapsed/Refractory Multiple Myeloma
NCT01677858Phase 2Completed
- Sponsor
- Amgen
- Start
- Jul 2012
- Primary completion
- Jul 2016
- Modality
- Irreversible Covalent Inhibitors, Reversible Covalent Inhibitors
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of carfilzomib in multiple myeloma (MM), sponsored by Amgen. Primary endpoints: Dose-limiting Toxicities at 28 days and Overall Response Rate at 33.6 weeks. Started Jul 2012; status: completed.
02
Drugs
carfilzomib
03
Conditions
multiple myeloma (MM)
Beyond the preview
Go deeper on NCT01677858.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT01677858.